{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:51:29Z","timestamp":1791507089239,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04434-8","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:47:56Z","timestamp":1784015276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pilot report of an anti-PD-1\/VEGF bispecific antibody for treating recurrent H3K27M-mutant diffuse midline gliomas"],"prefix":"10.1007","volume":"75","author":[{"given":"Li","family":"Yanchu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Hongbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xiaoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Meiling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiaoyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"3","key":"4434_CR1","first-page":"50","volume":"555","author":"WW Wc","year":"2026","unstructured":"Wc WW, Ma W, Wang Y (2026) Epigenetic mechanisms and therapeutic advances in diffuse midline glioma. Oncol Rep 555(3):50","journal-title":"Oncol Rep"},{"key":"4434_CR2","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","volume":"36","author":"M Lindsey Hoffman SEVvZ","year":"2018","unstructured":"Lindsey Hoffman SEVvZ M, Colditz N, Baugh J, Chaney B, Hoffmann M, Lane A, Fuller C, Miles L, Hawkins C, Bartels U, Bouffet E, Goldman S, Leary S, Foreman NK, Packer R, Warren KE, Broniscer A, Kieran MW, Minturn J, Comito M, Broxson E, Shih C-S, Khatua S, Chintagumpala M, Carret AS, Escorza NY, Hassall T, Ziegler DS, Gottardo N, Dholaria H, Doughman R, Benesch M, Drissi R, Nazarian J, Jabado N, Boddaert N, Varlet P, Giraud G, Castel D, Puget S, Jones C, Hulleman E, Modena P, Giagnacovo M, Antonelli M, Pietsch T, Gielen GH, Jones DTW, Sturm D, Pfister SM, Gerber NU, Grotzer MA, Pfaff E, von Bueren AO, Hargrave D, Solanki GA, Cvrlje FJ, Kaspers GJL, Vandertop WP, Grill J, Bailey S, Biassoni V, Massimino M, Calmon R, Sanchez E, Bison B, Warmuth-Metz M, Leach J, Jones B, van Vuurden DG, Kramm CM, Fouladi M (2018) Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol 36:1963\u20131972","journal-title":"J Clin Oncol"},{"issue":"1","key":"4434_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40364-025-00788-w","volume":"13","author":"L Zhang","year":"2025","unstructured":"Zhang L, Yang Y, Li Y, Wang C, Bian C, Wang H, Wang F (2025) Epigenetic regulation of histone modifications in glioblastoma: recent advances and therapeutic insights. Biomark Res 13(1):80","journal-title":"Biomark Res"},{"issue":"2","key":"4434_CR4","doi-asserted-by":"publisher","first-page":"108994","DOI":"10.1016\/j.celrep.2021.108994","volume":"35","author":"A Ehteda","year":"2021","unstructured":"Ehteda A, Simon S, Franshaw L, Giorgi FM, Liu J, Joshi S, Rouaen JRC, Pang CNI, Pandher R, Mayoh C et al (2021) Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Rep 35(2):108994","journal-title":"Cell Rep"},{"issue":"2","key":"4434_CR5","doi-asserted-by":"publisher","first-page":"e24877","DOI":"10.1016\/j.heliyon.2024.e24877","volume":"10","author":"Z Yang","year":"2024","unstructured":"Yang Z, Sun L, Chen H, Sun C, Xia L (2024) New progress in the treatment of diffuse midline glioma with H3K27M alteration. Heliyon 10(2):e24877","journal-title":"Heliyon"},{"key":"4434_CR6","doi-asserted-by":"publisher","first-page":"e18761429290327","DOI":"10.2174\/0118761429290327240222061812","volume":"17","author":"A Bombino","year":"2024","unstructured":"Bombino A, Magnani M, Conti A (2024) A promising breakthrough: the potential of VORASIDENIB in the treatment of low-grade glioma. Curr Mol Pharmacol 17:e18761429290327","journal-title":"Curr Mol Pharmacol"},{"issue":"2","key":"4434_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s11060-025-05347-9","volume":"176","author":"J Liu","year":"2025","unstructured":"Liu J, Ha JH, Abikenari M, Sjoholm MA, Annagiri S, Ravi K, Bergsneider BH, Verma R, Theodros D, Medikonda R et al (2025) Adaptive immunotherapeutic paradigms in diffuse midline glioma: integrating epigenetic reprogramming, neuron-glioma interactions, and tumor microenvironment modulation. J Neurooncol 176(2):144","journal-title":"J Neurooncol"},{"issue":"5","key":"4434_CR8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, Labanieh L, Hulleman E, Woo PJ, Rietberg SP et al (2018) Potent antitumor efficacy of anti-GD2 CAR T cells in H3\u2013K27M(+) diffuse midline gliomas. Nat Med 24(5):572\u2013579","journal-title":"Nat Med"},{"issue":"7903","key":"4434_CR9","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R et al (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603(7903):934\u2013941","journal-title":"Nature"},{"key":"4434_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03328-y","author":"X-L Feng","year":"2025","unstructured":"Feng X-L, Su G, Jia Q, Wu Q-H, Zhang Z-C (2025) B7-H3: a promising target for immunotherapy in glioma. Discov Oncol. https:\/\/doi.org\/10.1007\/s12672-025-03328-y","journal-title":"Discov Oncol"},{"issue":"12","key":"4434_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s11910-023-01317-8","volume":"23","author":"C Cacciotti","year":"2023","unstructured":"Cacciotti C, Wright KD (2023) Advances in treatment of diffuse midline gliomas. Curr Neurol Neurosci Rep 23(12):849\u2013856","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"4434_CR12","doi-asserted-by":"publisher","first-page":"2124058","DOI":"10.1080\/2162402X.2022.2124058","volume":"11","author":"JD Bernstock","year":"2022","unstructured":"Bernstock JD, Hoffman SE, Kappel AD, Valdes PA, Essayed W, Klinger NV, Kang KD, Totsch SK, Olsen HE, Schlappi CW et al (2022) Immunotherapy approaches for the treatment of diffuse midline gliomas. Oncoimmunology 11(1):2124058","journal-title":"Oncoimmunology"},{"issue":"8046","key":"4434_CR13","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM, Barsan V, Song KW, Kamens J, Baggott C et al (2025) Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas. Nature 637(8046):708\u2013715","journal-title":"Nature"},{"key":"4434_CR14","doi-asserted-by":"publisher","first-page":"103453","DOI":"10.1016\/j.ebiom.2021.103453","volume":"69","author":"G Price","year":"2021","unstructured":"Price G, Bouras A, Hambardzumyan D, Hadjipanayis CG (2021) Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma. EBioMedicine 69:103453","journal-title":"EBioMedicine"},{"issue":"5","key":"4434_CR15","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","volume":"31","author":"GV Long","year":"2025","unstructured":"Long GV, Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry KA, Diefenbach RJ, Gide TN, Shivalingam B, Buckland ME et al (2025) Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nat Med 31(5):1557\u20131566","journal-title":"Nat Med"},{"issue":"12","key":"4434_CR16","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P (2024) Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol 21(12):1354\u20131375","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"4434_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25(3):477\u2013486","journal-title":"Nat Med"},{"issue":"1","key":"4434_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41392-022-01274-7","volume":"8","author":"L Jing","year":"2023","unstructured":"Jing L, Qian Z, Gao Q, Sun R, Zhen Z, Wang G, Yang X, Li H, Guo T, Zhang W (2023) Diffuse midline glioma treated with epigenetic agent-based immunotherapy. Signal Transduct Target Ther 8(1):23","journal-title":"Signal Transduct Target Ther"},{"issue":"14","key":"4434_CR19","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K et al (2024) Intraventricular CARv3-TEAM-E T Cells in recurrent glioblastoma. N Engl J Med 390(14):1290\u20131298","journal-title":"N Engl J Med"},{"issue":"10","key":"4434_CR20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.trecan.2023.07.007","volume":"9","author":"BC Thomas","year":"2023","unstructured":"Thomas BC, Staudt DE, Douglas AM, Monje M, Vitanza NA, Dun MD (2023) CAR T cell therapies for diffuse midline glioma. Trends Cancer 9(10):791\u2013804","journal-title":"Trends Cancer"},{"issue":"9","key":"4434_CR21","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/neuonc\/noac117","volume":"24","author":"ML Persson","year":"2022","unstructured":"Persson ML, Douglas AM, Alvaro F, Faridi P, Larsen MR, Alonso MM, Vitanza NA, Dun MD (2022) The intrinsic and microenvironmental features of diffuse midline glioma: implications for the development of effective immunotherapeutic treatment strategies. Neuro Oncol 24(9):1408\u20131422","journal-title":"Neuro Oncol"},{"issue":"5","key":"4434_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.21147\/j.issn.1000-9604.2025.05.11","volume":"37","author":"W Xia","year":"2025","unstructured":"Xia W, Liu J, Chen R, Feng J, Wu L, Wang Y, Wang X, Song C, Mao W (2025) Molecular subtypes and prognostic signature rooted in disulfidptosis highlight tumor microenvironment in lung adenocarcinoma. Chin J Cancer Res 37(5):796\u2013820","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"4434_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41746-025-02172-2","volume":"8","author":"Z Gong","year":"2025","unstructured":"Gong Z, Du M, Li Y, Ye B, Huang Y, Gong H, Wang W, Chen L, Ding Z, Zhang P (2025) Machine learning identifies TIME subtypes linking EGFR mutations and immune states in lung adenocarcinoma. NPJ Digit Med 8(1):796","journal-title":"NPJ Digit Med"},{"issue":"6","key":"4434_CR24","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.21147\/j.issn.1000-9604.2025.06.11","volume":"37","author":"P Zhang","year":"2025","unstructured":"Zhang P, Liang X, Ye B, Wang X, Wang Y, Gong Z, Huang Y, Liu J, Huang C, Luo P (2025) Metabolic reprogramming signature predicts immunotherapy efficacy in lung adenocarcinoma: targeting SLC25A1 to overcome immune resistance. Chin J Cancer Res 37(6):1000\u20131019","journal-title":"Chin J Cancer Res"},{"key":"4434_CR25","doi-asserted-by":"crossref","unstructured":"L. Zhang WFF, Y. Zhao, Y. Yang, N. Zhou, L. Chen, Y. Huang, J. Chen, L. Zhuang, Y.Du, Q.Yu, W. Zhuang, Y. Zhao, M. Zhou, W. Zhang, Y. Zhang, Y. Wan, Y. Xia: Phase II results of ivonescimab (ivo) a novel PD-1\/VEGF bispecific in combination with chemotherapy for first-line treatment of patients (pts) with advanced\/metastatic squamous (Sq) non-small cell lung cancer (NSCLC). In: ESMO. 2024: 102647.","DOI":"10.1016\/j.esmoop.2024.102647"},{"key":"4434_CR26","doi-asserted-by":"crossref","unstructured":"Anuj Dilip Patel AA, Carlos Kamiya-Matsuoka, Ruitao Lin, Nazanin Majd, Barbara Jane O\u2019Brien, Chirag B. Patel, Shiao-Pei S. Weathers, Vinay K. Puduvalli: Dual targeting of VEGF and PD-1: A phase I\/II trial of ivonescimab, a novel bispecific antibody, in recurrent glioblastoma. In: ASCO. 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS2101"},{"issue":"1","key":"4434_CR27","first-page":"CD012532","volume":"1","author":"SM de Melo MEENdS","year":"2025","unstructured":"de Melo MEENdS SM, Torloni MR, Riera R, De Cicco K, Latorraca CO, Pereira Nunes Pinto AC (2025) Anti-PD-1 and anti-PD-L1 antibodies for glioma. Cochrane Database Syst Rev 1(1):CD012532","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"4434_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s11060-018-2991-5","volume":"140","author":"C Kline","year":"2018","unstructured":"Kline C, Liu SJ, Duriseti S, Banerjee A, Nicolaides T, Raber S, Gupta N, Haas-Kogan D, Braunstein S, Mueller S (2018) Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neurooncol 140(3):629\u2013638","journal-title":"J Neurooncol"},{"key":"4434_CR29","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/015314a0","volume":"15","author":"S Anna","year":"2019","unstructured":"Anna S (2019) Berghoff MP: Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome? Nature 15:314\u2013315","journal-title":"Nature"},{"issue":"6","key":"4434_CR30","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41416-022-01864-w","volume":"127","author":"KJ Habashy","year":"2022","unstructured":"Habashy KJ, Mansour R, Moussalem C, Sawaya R, Massaad MJ (2022) Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. Br J Cancer 127(6):976\u2013987","journal-title":"Br J Cancer"},{"issue":"9","key":"4434_CR31","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41388-017-0024-z","volume":"37","author":"VA Boussiotis","year":"2018","unstructured":"Boussiotis VA, Charest A (2018) Immunotherapies for malignant glioma. Oncogene 37(9):1121\u20131141","journal-title":"Oncogene"},{"issue":"6","key":"4434_CR32","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","volume":"29","author":"F Nassiri","year":"2023","unstructured":"Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H et al (2023) Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial. Nat Med 29(6):1370\u20131378","journal-title":"Nat Med"},{"issue":"10","key":"4434_CR33","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","volume":"18","author":"NB Michael Weller","year":"2017","unstructured":"Michael Weller NB, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O\u2019Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. lancet oncol 18(10):1373\u20131385","journal-title":"lancet oncol"},{"key":"4434_CR34","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1093\/neuonc\/noae031","volume":"26","author":"I Arrillaga-Romany","year":"2024","unstructured":"Arrillaga-Romany I, Lassman A, McGovern SL, Mueller S, Nabors B, van den Bent M, Vogelbaum MA, Allen JE, Melemed AS, Tarapore RS et al (2024) ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro Oncol 26:S173\u2013S181","journal-title":"Neuro Oncol"},{"issue":"11","key":"4434_CR35","doi-asserted-by":"publisher","first-page":"e7350","DOI":"10.1002\/cam4.7350","volume":"13","author":"L Zhang","year":"2024","unstructured":"Zhang L, Ren Y, Peng Y, Luo Y, Liu Y, Wang X, Yang Y, Liu L, Ai P, Yang X et al (2024) Tumor treating fields for newly diagnosed high-grade glioma based on the criteria of 2021 WHO CNS5: a retrospective analysis of Chinese patients in a single center. Cancer Med 13(11):e7350","journal-title":"Cancer Med"},{"issue":"1","key":"4434_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/0115665232356703250325075309","volume":"26","author":"OIG Beylerli","year":"2026","unstructured":"Beylerli OIG, Musaev E, Ilyasova T, Roumiantsev S, Chekhonin V (2026) Non-coding RNAs-based therapy and angiogenesis: a new era for the management of gliomas. Curr Gene Ther 26(1):85\u2013115","journal-title":"Curr Gene Ther"},{"issue":"2","key":"4434_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A-L, Latreche S, Bergaya S, Benhamouda N, Tanchot C et al (2015) VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 212(2):139\u2013148","journal-title":"J Exp Med"},{"issue":"6","key":"4434_CR38","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz GT, Santoro SP, Wang L-P, Garrabrant T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F, Coukos G (2014) Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 20(6):607\u2013615","journal-title":"Nat Med"},{"issue":"1","key":"4434_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"S Priti","year":"2020","unstructured":"Priti S (2020) Hegde DSC: Top 10 challenges in cancer immunotherapy. Immunity 52(1):17\u201335","journal-title":"Immunity"},{"key":"4434_CR40","doi-asserted-by":"publisher","first-page":"118023","DOI":"10.1016\/j.biopha.2025.118023","volume":"186","author":"H Mahaki","year":"2025","unstructured":"Mahaki H, Nobari S, Tanzadehpanah H, Babaeizad A, Kazemzadeh G, Mehrabzadeh M, Valipour A, Yazdinezhad N, Manoochehri H, Yang P et al (2025) Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: therapeutic strategies and insights. Biomed Pharmacother 186:118023","journal-title":"Biomed Pharmacother"},{"key":"4434_CR41","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","volume":"9","author":"J Yang","year":"2018","unstructured":"Yang J, Yan J, Liu B (2018) Targeting VEGF\/VEGFR to modulate antitumor immunity. Front Immunol 9:978","journal-title":"Front Immunol"},{"issue":"4","key":"4434_CR42","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.immuni.2025.02.017","volume":"58","author":"MR Benmebarek","year":"2025","unstructured":"Benmebarek MR, Oguz C, Seifert M, Ruf B, Myojin Y, Bauer KC, Huang P, Ma C, Villamor-Paya M, Rodriguez-Matos F et al (2025) Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. Immunity 58(4):926\u2013945","journal-title":"Immunity"},{"issue":"20","key":"4434_CR43","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, Kudo M, Breder V, Merle P, Kaseb AO et al (2020) Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894\u20131905","journal-title":"N Engl J Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04434-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04434-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04434-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:32:49Z","timestamp":1791505969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04434-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4434"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04434-8","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"25 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the patient for the present report, and this study was approved by Ethics Committee of West China hospital.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the manuscript for publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"247"}}